[go: up one dir, main page]

HUP0101546A2 - Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére - Google Patents

Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére

Info

Publication number
HUP0101546A2
HUP0101546A2 HU0101546A HUP0101546A HUP0101546A2 HU P0101546 A2 HUP0101546 A2 HU P0101546A2 HU 0101546 A HU0101546 A HU 0101546A HU P0101546 A HUP0101546 A HU P0101546A HU P0101546 A2 HUP0101546 A2 HU P0101546A2
Authority
HU
Hungary
Prior art keywords
alcohol
treatment
nmda receptor
receptor complex
opioid antagonist
Prior art date
Application number
HU0101546A
Other languages
English (en)
Inventor
Yves Bonhomme
Martine Daoust
Philippe Durbin
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipha filed Critical Lipha
Publication of HUP0101546A2 publication Critical patent/HUP0101546A2/hu
Publication of HUP0101546A3 publication Critical patent/HUP0101546A3/hu
Publication of HU226555B1 publication Critical patent/HU226555B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány alkohol- és drogfüggőség kezelésére alkalmas gyógyászatikészítményekre vonatkozik, melyek terápiásan hatásos mennyiségbentartalmaznak: (i) opioid antagonistát, például naltrexont vagynaloxont; és (ii) NMDA-receptor komplex modulátort, közelebbrőlspermidin-kötőhelyi modulátort. Továbbá a találmány kiterjedugyanezeket a hatóanyagokat tartalmazó kitekre. A fenti hatóanyag-kombinációval eredményesen és hatékonyan kezelhetnek alkohol- ésdrogfüggőséget. Ó
HU0101546A 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator HU226555B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (3)

Publication Number Publication Date
HUP0101546A2 true HUP0101546A2 (hu) 2001-09-28
HUP0101546A3 HUP0101546A3 (en) 2002-10-28
HU226555B1 HU226555B1 (en) 2009-03-30

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101546A HU226555B1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Country Status (18)

Country Link
US (1) US6512009B1 (hu)
EP (2) EP0945133A1 (hu)
KR (1) KR20010034678A (hu)
AT (1) ATE230993T1 (hu)
AU (1) AU758569B2 (hu)
BR (1) BR9909138A (hu)
CA (1) CA2325739C (hu)
CZ (1) CZ296367B6 (hu)
DE (1) DE69904922T2 (hu)
DK (1) DK1063995T3 (hu)
ES (1) ES2190205T3 (hu)
HK (1) HK1032542A1 (hu)
HU (1) HU226555B1 (hu)
NO (1) NO319313B1 (hu)
PL (1) PL193241B1 (hu)
RU (1) RU2226107C2 (hu)
SK (1) SK284623B6 (hu)
WO (1) WO1999048500A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
ATE482695T1 (de) * 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
MXPA05012768A (es) * 2003-05-30 2006-02-22 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20100041689A1 (en) * 2006-12-19 2010-02-18 University Of Virginia Patent Foundation Combined Effects of Topiramate and Ondansetron on Alcohol Consumption
CA2706658A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
HK1151091A1 (en) 2008-02-28 2012-01-20 Univ Virginia Patent Found Serotonin transporter gene and treatment of alcoholism
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
NZ605709A (en) 2010-07-02 2014-08-29 Univ Virginia Patent Found Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EP3045173A3 (en) 2011-09-09 2016-09-14 The University of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
US20240350433A1 (en) * 2021-08-17 2024-10-24 Yale University Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0828489A4 (en) * 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatments using naltrexone and related compounds

Also Published As

Publication number Publication date
NO20004788D0 (no) 2000-09-25
SK14282000A3 (sk) 2001-05-10
EP1063995A1 (en) 2001-01-03
DK1063995T3 (da) 2003-03-10
CA2325739A1 (en) 1999-09-30
DE69904922T2 (de) 2004-01-08
PL343069A1 (en) 2001-07-30
EP1063995B1 (en) 2003-01-15
WO1999048500A1 (en) 1999-09-30
KR20010034678A (ko) 2001-04-25
ES2190205T3 (es) 2003-07-16
DE69904922D1 (de) 2003-02-20
CA2325739C (en) 2007-05-15
ATE230993T1 (de) 2003-02-15
NO20004788L (no) 2000-11-24
PL193241B1 (pl) 2007-01-31
HU226555B1 (en) 2009-03-30
BR9909138A (pt) 2000-12-05
SK284623B6 (sk) 2005-08-04
AU3522699A (en) 1999-10-18
HK1032542A1 (en) 2001-07-27
EP0945133A1 (en) 1999-09-29
HUP0101546A3 (en) 2002-10-28
NO319313B1 (no) 2005-07-11
AU758569B2 (en) 2003-03-27
CZ20003525A3 (cs) 2001-04-11
US6512009B1 (en) 2003-01-28
RU2226107C2 (ru) 2004-03-27
CZ296367B6 (cs) 2006-02-15

Similar Documents

Publication Publication Date Title
HUP0101546A2 (hu) Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
WO2000071125A3 (de) Pharmazeutisches präparat mit dem wirkstoff diamorphin und seine verwendung in einem verfahren zur behandlung der opiatsucht
HUP0201711A2 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
WO1999017755A3 (en) Medicaments
ATE256460T1 (de) Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler
RU2000126790A (ru) Композиция, предназначенная для лечения алкогольной и лекарственной зависимости, содержащая опиоидный антагонист и модулятор nmda рецепторного комплекса
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
IL162616A (en) Benzooxazine, benzothiazine and quinoline analogues as cholinergic receptor agonists and use thereof in the preparation of medicaments for treating diseases
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
GB9917822D0 (en) Nmda antagonist
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
BR0212714A (pt) Combinação de opiáceos selecionados com antagonistas muscarìnicos destinados ao tratamento da incontinência urinária
SE9603725D0 (sv) New teatment
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
HUP0303285A2 (hu) Gyenge opioidok és vegyes opioid-agonisták/-antagonisták felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény elõállítására
WO2001016355A3 (de) In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
BRPI0413608A (pt) composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees